Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In univariate analyses, beliefs about the effectiveness of calcium and vitamin D and the baseline guess about allocation were not significantly associated with RIF.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a partial factorial-design, randomized, controlled trial of calcium and vitamin D to prevent colorectal adenoma recurrence at 11 centers in the United States.

Source: Abstract.

Participants in the full factorial randomization (calcium, vitamin D, both, or neither) received a placebo during a 3-month single-blinded run-in; women electing to take calcium enrolled in a two-group randomization (calcium with vitamin D, or calcium alone) and received calcium during the run-in.

Source: Abstract.

Participants were recruited between 2004 and 2008 at 11 clinical centers in the continental United States and Puerto Rico following a complete colonoscopy, during which at least one colorectal adenoma was removed and none remained after the procedure.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Randomized controlled trials: who fails run-in?

Randomised controlled trial · Trials · 2016

Original publication title

Randomized controlled trials: who fails run-in?

Judy R. Rees; Leila A. Mott; Elizabeth L. Barry; John A. Baron; Jane C. Figueiredo; Douglas J. Robertson; Robert S. Bresalier; Janet L. Peacock

© Rees et al. 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

There were few common baseline predictors of run-in failure in the three randomization groups. However, heterogeneity in run-in failure associated with study center, and missing SAQ data reflect potential opportunities for intervention to improve trial efficiency and retention.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Early identification of participants at risk of run-in failure (RIF) may present opportunities to improve trial efficiency and generalizability.

Source: Background

Abstract: What methods does the paper describe?

We conducted a partial factorial-design, randomized, controlled trial of calcium and vitamin D to prevent colorectal adenoma recurrence at 11 centers in the United States. At baseline, participants completed two self-administered questionnaires (SAQs) and a questionnaire administered by staff. Participants in the full factorial randomization (calcium, vitamin D, both, or neither) received a placebo during a 3-month single-blinded run-in; women electing to take calcium enrolled in a two-group randomization (calcium with vitamin D, or calcium alone) and received calcium during the run-in.

Using logistic regression models, we examined baseline factors associated with RIF in three subgroups: men (N = 1606) and women (N = 301) in the full factorial randomization and women in the two-group randomization (N = 666).

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (doi:10.1186/s13063-016-1451-9) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

Overall, 314/2573 (12 %) participants failed run-in; 211 (67 %) took fewer than 80 % of their tablets (poor adherence), and 103 (33 %) withdrew or were uncooperative. In multivariable models, 8: to 13-fold variation was seen by study center in odds of RIF risk in the two largest groups. In men, RIF decreased with age (adjusted odds ratio [OR] per 5 years 0.85 [95 % confidence interval, CI; 0.76 to 0.96]) and was associated with being single (OR 1.65 [95 % CI; 1.10 to 2.47]), not graduating from high school (OR 2.77 [95 % CI; 1.58 to 4.85]), and missing SAQ data (OR 1.97 [1.40 to 2.76]).

Among women, RIF was associated primarily with health-related factors; RIF risk was lower with higher physical health score (OR 0.73 [95 % CI; 0.62 to 0.86]) and baseline multivitamin use (OR 0.44 [95 % CI; 0.26 to 0.75]). Women in the 5-year colonoscopy surveillance interval were at greater risk of RIF than those with 3-year follow-up (OR 1.91 [95 % CI; 1.08 to 3.37]), and the number of prescription medicines taken was also positively correlated with RIF (p = 0.03). Perceived toxicities during run-in were associated with 12: to 29-fold significantly increased odds of RIF.

Source: Results

Abstract: Conclusions

There were few common baseline predictors of run-in failure in the three randomization groups. However, heterogeneity in run-in failure associated with study center, and missing SAQ data reflect potential opportunities for intervention to improve trial efficiency and retention.

Source: Conclusions
Authors’ abstract

Background

Early identification of participants at risk of run-in failure (RIF) may present opportunities to improve trial efficiency and generalizability.

Methods

We conducted a partial factorial-design, randomized, controlled trial of calcium and vitamin D to prevent colorectal adenoma recurrence at 11 centers in the United States. At baseline, participants completed two self-administered questionnaires (SAQs) and a questionnaire administered by staff. Participants in the full factorial randomization (calcium, vitamin D, both, or neither) received a placebo during a 3-month single-blinded run-in; women electing to take calcium enrolled in a two-group randomization (calcium with vitamin D, or calcium alone) and received calcium during the run-in.

Using logistic regression models, we examined baseline factors associated with RIF in three subgroups: men (N = 1606) and women (N = 301) in the full factorial randomization and women in the two-group randomization (N = 666).

Results

Overall, 314/2573 (12 %) participants failed run-in; 211 (67 %) took fewer than 80 % of their tablets (poor adherence), and 103 (33 %) withdrew or were uncooperative. In multivariable models, 8: to 13-fold variation was seen by study center in odds of RIF risk in the two largest groups. In men, RIF decreased with age (adjusted odds ratio [OR] per 5 years 0.85 [95 % confidence interval, CI; 0.76 to 0.96]) and was associated with being single (OR 1.65 [95 % CI; 1.10 to 2.47]), not graduating from high school (OR 2.77 [95 % CI; 1.58 to 4.85]), and missing SAQ data (OR 1.97 [1.40 to 2.76]).

Among women, RIF was associated primarily with health-related factors; RIF risk was lower with higher physical health score (OR 0.73 [95 % CI; 0.62 to 0.86]) and baseline multivitamin use (OR 0.44 [95 % CI; 0.26 to 0.75]). Women in the 5-year colonoscopy surveillance interval were at greater risk of RIF than those with 3-year follow-up (OR 1.91 [95 % CI; 1.08 to 3.37]), and the number of prescription medicines taken was also positively correlated with RIF (p = 0.03). Perceived toxicities during run-in were associated with 12: to 29-fold significantly increased odds of RIF.

Conclusions

There were few common baseline predictors of run-in failure in the three randomization groups. However, heterogeneity in run-in failure associated with study center, and missing SAQ data reflect potential opportunities for intervention to improve trial efficiency and retention.

Trial registration

ClinicalTrials.gov: NCT00153816. Registered September 2005.

Electronic supplementary material

The online version of this article (doi:10.1186/s13063-016-1451-9) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Randomized controlled trials: who fails run-in?

Judy R. Rees; Leila A. Mott; Elizabeth L. Barry; John A. Baron; Jane C. Figueiredo; Douglas J. Robertson; Robert S. Bresalier; Janet L. Peacock

Trials · 2016

© Rees et al. 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/100000054National Cancer InstituteR03CA178272http://dx.doi.org/10.13039/100000054National Cancer InstituteR01CA098286

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T09:15:45.115599+00:00

DOI: 10.1186/s13063-016-1451-9 · PMC4966775